Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2021-02-03

Imcyse Enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis

2021-02-03

Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes

2021-01-08

The beginning of the end for Type I diabetes: A new view from immunotherapy science

2020-09-07

Imcyse Announces the Appointment of Denis Bedoret as Chief Executive Officer

2020-07-28

Imcyse Awarded Subsidy from the Walloon Region for Neuromyelitis Optica Spectrum Disorder Study

Go Back